Princess Maxima Center For Pediatric Oncology

5 trials 5 recruiting Academic / non-commercial

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

5 Recruiting

0 Completed trials

19 Countries active

22 Unique IMPs

N/A Results reported

Phase III

Phase I/II

Phase III: 1 Phase I/II: 4

Oversight events:

17 temporary halts 2 urgent safety measures 2 corrective measures across 1 trial

View oversight register →

Top IMPs

VENETOCLAX 2 [18F]META-FLUOROBENZYLGUANIDINE 1 ASPARAGINASE 1 BLINATUMOMAB 1 CYCLOPHOSPHAMIDE MONOHYDRATE 1 CYTARABINE 1 DASATINIB 1 DAUNORUBICIN 1 DEXAMETHASONE 1 DEXAMETHASONE SODIUM PHOSPHATE 1 ETOPOSIDE 1 HYDROCORTISONE 1

All trials

5 total

Clinical study of ruxolitinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with mutations in the IL-7R/JAK-S… Recruiting

2022-501867-42-01 Phase I/II 11 countries RUXOLITINIB; VENETOCLAX
Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA… Recruiting

2022-501866-22-00 Phase I/II 11 countries DASATINIB; VENETOCLAX
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Phase III 19 countries ASPARAGINASE; BLINATUMOMAB; CYCLOPHOSPHAMIDE MONOHYDRATE; CYTARABINE; DAUNORUBIC…
mFBG PET-CT for neuroblastoma Recruiting

2022-501694-39-01 Phase I/II 1 country [18F]META-FLUOROBENZYLGUANIDINE
International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies … Recruiting

2022-501869-41-00 Phase I/II 11 countries TRAMETINIB

Showing 1–5 of 5 trials

← All sponsors A–Z